DPP4 and myotonic dystrophy type 1: Basic research suggests that DPP-4 inhibitors may have positive effects on muscle mitochondrial function and fibrosis (133, 134), but there is currently no evidence to support whether these effects translate into clinical benefits in terms of muscle strength, muscle stiffness, or disease progression in DM1 patients.